Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Omaha, Nebraska 68131


Purpose:

It is recommended that patients who have drug-eluting stents placed in their coronary arteries take aspirin and Plavix (Clopidogrel) for at least a year. Patients who stop taking these antiplatelet drugs or who have resistance to the antiplatelet effects of these drugs are at a higher risk of clots occurring inside the stents which may result in a heart attack. At the present time, it is unknown if increasing the doses of the antiplatelet agents is effective in overcoming this resistance. The purpose of this project is to identify patients with antiplatelet drug resistance and to test whether an increase in the Plavix (Clopidogrel) dose overcomes antiplatelet drug resistance.


Criteria:

Inclusion Criteria: - Required Coronary Artery Angioplasty with a drug-eluting stent deployment Exclusion Criteria: - The last drug-eluting stent placed greater than 2 weeks prior - Aspirin or Plavix (Clopidogrel) allergy or contraindication


NCT ID:

NCT00589862


Primary Contact:

Principal Investigator
Daniel Hilleman, PharmD
Creighton University


Backup Contact:

N/A


Location Contact:

Omaha, Nebraska 68131
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 18, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.